Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/095—Neisseria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55505—Inorganic adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
  • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide

Definitions

• This invention is in the field of vaccination and, in particular, vaccination against disease caused by pathogenic bacteria in the genus Neisseria, such as N.meningitidis (meningococcus).
• Neisseria meningitidis is a Gram-negative encapsulated bacterium which colonises the upper respiratory tract of approximately 10% of human population. Approximately once in every 10,000 colonised people (or once in 100,000 population) the bacterium enters the blood stream where it multiplies and causes sepsis. From the blood stream the bacterium can cross the blood-brain barrier and cause meningitis. Both diseases are devastating and can kill 5-15% of affected children and young adults within hours, despite the availability of effective antibiotics. Up to 25% of those who survive are left with permanent sequelae.
• NadA protein is disclosed in references 173 and 174. These references disclose three distinct alleles of NadA, although some minor variations were found e.g. serogroup C strain ISS1024 has a variant of allele 2 with a single heptad repeat deletion, serogroup C strains ISS759 and 973-1720 both contain a variant of allele 3 with a single amino acid mutation in the leader peptide, and serogroup B strain 95330 contains a recombination of alleles 1 and 2.
• SEQ ID NO: 1 was identified. This protein is a recombinant of known alleles 2 and 3.
• the invention provides a protein comprising an amino acid sequence having at least 50% (e.g. 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more e.g. 100%) sequence identity to SEQ ID NO: 1, and/or comprising an amino acid sequence consisting of a fragment of at least 7 (e.g. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250) contiguous amino acids from SEQ ID NO: 1.
• amino acid sequence having at least 50% (e.g. 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more e.g. 100%) sequence identity to SEQ ID NO: 1, and/or comprising an amino acid sequence consisting of a fragment of at least 7 (e.g. 8, 9, 10, 11, 12, 13, 14,
• Preferred fragments include: (a) fragments which comprise an epitope, and preferably a bactericidal epitope; (b) fragments common to SEQ ID NO: 1 and at least one of the NadA sequences disclosed in references 173 and 174; (c) SEQ ID NO: 1 with 1 or more ( e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120 or more, etc.) N-terminal residues deleted; (d) SEQ ID NO: 1 with 1 or more (e.g.
• Preferred amino acid sequences with ⁇ 100% identity to SEQ ID NO: 1 are allelic variants, homologs, orthologs, paralogs, mutants etc. thereof. It is preferred that one or more of the differences in allelic variants, homologs, orthologs, paralogs or mutants, compared to SEQ ID NO: 1, involves a conservative amino acid replacement.
• a characteristic of preferred proteins of the invention is the ability to induce bactericidal anti-meningococcal antibodies after administration to a host animal.
• Proteins can be prepared by various means e.g. by chemical synthesis (at least in part), by digesting longer polypeptides using proteases, by translation from RNA, by purification from cell culture ( e.g. from recombinant expression or from N.meningitidis culture). etc.
• Heterologous expression in an E.coli host is a preferred expression route (e.g. strains DH5 ⁇ , BL21(DE 3 ), BLR, etc.).
• Proteins of the invention may be attached or immobilised to a solid support.
• Proteins of the invention may comprise a detectable label e.g. a radioactive label, a fluorescent label, or a biotin label. This is particularly useful in immunoassay techniques.
• Proteins can take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, disulfide bridges, etc.). Proteins are preferably meningococcal proteins.
• Proteins are preferably prepared in substantially pure or substantially isolated form ( i.e. substantially free from other Neisserial or host cell proteins) or substantially isolated form.
• the proteins are provided in a non-naturally occurring environment e.g. they are separated from their naturally-occurring environment.
• the subject protein is present in a composition that is enriched for the protein as compared to a control.
• purified protein is provided, whereby purified is meant that the protein is present in a composition that is substantially free of other expressed proteins, where by substantially free is meant that less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of other expressed proteins.
• protein refers to amino acid polymers of any length.
• the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
• the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
• proteins containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc .
• Proteins can occur as single chains or associated chains.
• the invention provides nucleic acid encoding a protein of the invention as defined above.
• the invention also provides nucleic acid comprising: (a) a fragment of at least n consecutive nucleotides from said nucleic acid, wherein n is 10 or more (e.g. 12, 14, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500 or more); and/or (b) a sequence having at least 50% ( e.g. 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) sequence identity to said nucleic acid.
• nucleic acid which can hybridise to nucleic acid encoding a protein of the invention, preferably under "high stringency” conditions (e.g. 65°C in a 0.1xSSC, 0.5% SDS solution).
• Nucleic acids of the invention can be used in hybridisation reactions (e.g. Northern or Southern blots, or in nucleic acid microarrays or 'gene chips') and amplification reactions (e.g. PCR, SDA, SSSR, LCR, TMA, NASBA, etc.) and other nucleic acid techniques.
• hybridisation reactions e.g. Northern or Southern blots, or in nucleic acid microarrays or 'gene chips'
• amplification reactions e.g. PCR, SDA, SSSR, LCR, TMA, NASBA, etc.
• Nucleic acids of the invention can be prepared in many ways e.g. by chemical synthesis in whole or part, by digesting longer polynucleotides using nucleases (e.g. restriction enzymes), from genomic or cDNA libraries, from the bacterium itself, etc.
• nucleases e.g. restriction enzymes
• Nucleic acids of the invention can take various forms e.g. single-stranded, double-stranded, vectors, primers, probes, labelled, unlabelled, etc.
• Nucleic acids of the invention are preferably in isolated or substantially isolated form.
• the invention includes nucleic acid comprising sequences complementary to those described above e.g. for antisense or probing, or for use as primers.
• nucleic acid includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
• Nucleic acid according to the invention may be labelled e.g. with a radioactive or fluorescent label. This is particularly useful where the nucleic acid is to be used in nucleic acid detection techniques e.g. where the nucleic acid is a primer or as a probe for use in techniques such as PCR, LCR, TMA, NASBA, etc.
• the invention also provides vectors comprising nucleotide sequences of the invention (e.g. cloning or expression vectors, such as those suitable for nucleic acid immunisation) and host cells transformed with such vectors.
• nucleotide sequences of the invention e.g. cloning or expression vectors, such as those suitable for nucleic acid immunisation
• compositions of the invention include a small number (e.g. fewer than t antigens, where t is 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 or 3) of purified serogroup B antigens. It is particularly preferred that the composition should not include complex or undefined mixtures of antigens e.g. it is preferred not to include outer membrane vesicles in the composition.
• the antigens are preferably expressed recombinantly in a heterologous host and then purified.
• a composition of the invention may include another neisserial antigen, as a vaccine which targets more than one antigen per bacterium decreases the possibility of selecting escape mutants.
• Neisserial antigens for inclusion in the compositions include proteins comprising:
• the composition may include antigens for immunising against other diseases or infections.
• the composition may include one or more of the following further antigens:
• composition may comprise one or more of these further antigens.
• Toxic protein antigens may be detoxified where necessary (e.g. detoxification of pertussis toxin by chemical and/or genetic means [35]).
• diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens. DTP combinations are thus preferred.
• Saccharide antigens are preferably in the form of conjugates.
• Carrier proteins for the conjugates include the N.meningitidis outer membrane protein [63], synthetic peptides [64,65], heat shock proteins [66,67], pertussis proteins [68,69], protein D from H.influenzae [70], cytokines [71], lymphokines [71], streptococcal proteins, hormones [71], growth factors [71], toxin A or B from C.difficile [72], iron-uptake proteins [73], etc.
• a preferred carrier protein is the CRM197 diphtheria toxoid [74].
• Antigens in the composition will typically be present at a concentration of at least 1 ⁇ g/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.
• Immunogenic compositions of the invention may be used therapeutically (i. e. to treat an existing infection) or prophylactically (i.e. to prevent future infection).
• nucleic acid preferably DNA e.g. in the form of a plasmid
• encoding the antigen may be used.
• compositions of the invention include one, two or three of: (a) saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A; (b) a saccharide antigen from Haemophilus influenzae type B; and/or (c) an antigen from Streptococcus pneumoniae.
• the recently-approved serogroup C vaccines include conjugated saccharides. MenjugateTM and MeningitecTM have oligosaccharide antigens conjugated to a CRM 197 carrier, whereas NeisVac-CTM uses the complete polysaccharide (de-O-acetylated) conjugated to a tetanus toxoid carrier.
• the proposed MenActraTM vaccine contains conjugated capsular saccharide antigens from each of serogroups Y, W135, C and A.
• compositions of the present invention preferably include capsular saccharide antigens from one or more of meningococcus serogroups Y, W135, C and (optionally) A, wherein the antigens are conjugated to carrier protein(s) and/or are oligosaccharides.
• the composition may include a capsular saccharide antigen from: serogroup C; serogroups A and C; serogroups A, C and W135; serogroups A, C and Y; serogroups C, W135 and Y; or from all four of serogroups A, C, W135 and Y.
• a typical quantity of each meningococcal saccharide antigen per dose is between 1 ⁇ g and 20 ⁇ g e.g. about 1 ⁇ g, about 2.5 ⁇ g, about 4 ⁇ g, about 5 ⁇ g, or about 10 ⁇ g (expressed as saccharide).
• the ratio (w/w) of MenA saccharide:MenC saccharide may be greater than 1 ( e.g. 2:1, 3:1, 4:1, 5:1, 10:1 or higher).
• the ratio (w/w) of MenY saccharide:MenW135 saccharide may be greater than 1 ( e.g. 2:1, 3:1, 4:1, 5:1, 10:1 or higher) and/or that the ratio (w/w) of MenY saccharide:MenC saccharide may be less than 1 ( e.g.
• Preferred ratios (w/w) for saccharides from serogroups A:C:W135:Y are: 1:1:1:1; 1:1:1:2; 2:1:1:1; 4:2:1:1; 8:4:2:1; 4:2:1:2; 8:4:1:2; 4:2:2:1; 2:2:1:1; 4:4:2:1; 2:2:1:2; 4:4:1:2; and 2:2:2:1.
• Preferred ratios (w/w) for saccharides from serogroups C:W135:Y are: 1:1:1; 1:1:2; 1:1:1; 2:1:1; 4:2:1; 2:1:2; 4:1:2; 2:2:1; and 2:1:1. Using a substantially equal mass of each saccharide is preferred.
• Capsular saccharides will generally be used in the form of oligosaccharides. These are conveniently formed by fragmentation of purified capsular polysaccharide ( e.g. by hydrolysis), which will usually be followed by purification of the fragments of the desired size.
• Fragmentation of polysaccharides is preferably performed to give a final average degree of polymerisation (DP) in the oligosaccharide of less than 30 (e.g. between 10 and 20, preferably around 10 for serogroup A; between 15 and 25 for serogroups W135 and Y, preferably around 15-20; between 12 and 22 for serogroup C; etc .).
• DP can conveniently be measured by ion exchange chromatography or by colorimetric assays [76].
• the hydrolysate will generally be sized in order to remove short-length oligosaccharides [24]. This can be achieved in various ways, such as ultrafiltration followed by ion-exchange chromatography. Oligosaccharides with a degree of polymerisation of less than or equal to about 6 are preferably removed for serogroup A, and those less than around 4 are preferably removed for serogroups W 135 and Y.
• MenC saccharide antigens are disclosed in reference 75, as used in MenjugateTM.
• the saccharide antigen may be chemically modified. This is particularly useful for reducing hydrolysis for serogroup A [77; see below]. De-O-acetylation of meningococcal saccharides can be performed. For oligosaccharides, modification may take place before or after depolymerisation.
• composition of the invention includes a MenA saccharide antigen
• the antigen is preferably a modified saccharide in which one or more of the hydroxyl groups on the native saccharide has/have been replaced by a blocking group [77]. This modification improves resistance to hydrolysis.
• the number of monosaccharide units having blocking groups can vary. For example, all or substantially all the monosaccharide units may have blocking groups. Alternatively, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the monosaccharide units may have blocking groups. At least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 monosaccharide units may have blocking groups.
• the number of blocking groups on a monosaccharide unit may vary.
• the number of blocking groups on a monosaccharide unit may be 1 or 2.
• the blocking group will generally be at the 4 position and/or 3-position of the monosaccharide units.
• the terminal monosaccharide unit may or may not have a blocking group instead of its native hydroxyl. It is preferred to retain a free anomeric hydroxyl group on a terminal monosaccharide unit in order to provide a handle for further reactions ( e.g. conjugation).
• Anomeric hydroxyl groups can be converted to amino groups (-NH 2 or -NH-E, where E is a nitrogen protecting group) by reductive amination (using, for example, NaBH 3 CN/NH 4 Cl), and can then be regenerated after other hydroxyl groups have been converted to blocking groups.
• Blocking groups to replace hydroxyl groups may be directly accessible via a derivatizing reaction of the hydroxyl group i.e. by replacing the hydrogen atom of the hydroxyl group with another group.
• Suitable derivatives of hydroxyl groups which act as blocking groups are, for example, carbamates, sulfonates, carbonates, esters, ethers (e.g. silyl ethers or alkyl ethers) and acetals.
• Some specific examples of such blocking groups are allyl, Aloc, benzyl, BOM, t-butyl, trityl, TBS, TBDPS, TES, TMS, TIPS, PMB, MEM, MOM, MTM, THP, etc.
• blocking groups that are not directly accessible and which completely replace the hydroxyl group include C 1-12 alkyl, C 3-12 alkyl, C 5-12 aryl, C 5-12 aryl-C 1-6 alkyl, NR 1 R 2 (R 1 and R 2 are defined in the following paragraph), H, F, Cl, Br, CO 2 H, CO 2 (C 1-6 alkyl), CN, CF 3 , CCl 3 , etc.
• Preferred blocking groups are electron-withdrawing groups.
• Preferred blocking groups are of the formula: -O-X-Y or -OR 3 wherein: X is C(O), S(O) or SO 2 ; Y is C 1-12 alkyl, C 1-12 alkoxy, C 3-12 cycloalkyl, C 5-12 aryl or C 5-12 aryl-C 1-6 alkyl, each of which may optionally be substituted with 1, 2 or 3 groups independently selected from F, Cl, Br, CO 2 H, CO 2 (C 1-6 alkyl), CN, CF 3 or CCl 3 ; or Y is NR 1 R 2 ; R 1 and R 2 are independently selected from H, C 1-12 alkyl, C 3-12 cycloalkyl, C 5-12 aryl, C 5-12 aryl-C 1-6 alkyl; or R 1 and R 2 may be joined to form a C 3-12 saturated heterocyclic group; R 3 is C 1-12 alkyl or C 3-12 cycloalkyl, each of which may optionally be substituted with 1, 2 or
• R 3 is C 1-12 alkyl or C 3-12 cycloalkyl, it is typically substituted with 1, 2 or 3 groups as defined above.
• R 1 and R 2 are joined to form a C 3-12 saturated heterocyclic group, it is meant that R 1 and R 2 together with the nitrogen atom form a saturated heterocyclic group containing any number of carbon atoms between 3 and 12 ( e.g. C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 ).
• the heterocyclic group may contain 1 or 2 heteroatoms (such as N, O or S) other than the nitrogen atom.
• Examples of C 3-12 saturated heterocyclic groups are pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, imidazolidinyl, azetidinyl and aziridinyl.
• Blocking groups -O-X-Y and -OR 3 can be prepared from -OH groups by standard derivatizing procedures, such as reaction of the hydroxyl group with an acyl halide, alkyl halide, sulfonyl halide, etc.
• the oxygen atom in -O-X-Y is preferably the oxygen atom of the hydroxyl group, while the -X-Y group in -O-X-Y preferably replaces the hydrogen atom of the hydroxyl group.
• the blocking groups may be accessible via a substitution reaction, such as a Mitsonobu-type substitution.
• a substitution reaction such as a Mitsonobu-type substitution.
• the blocking group is -OC(O)CF 3 [78], or a carbamate group -OC(O)NR 1 R 2 , where R 1 and R 2 are independently selected from C 1-6 alkyl. More preferably, R 1 and R 2 are both methyl i.e. the blocking group is -OC(O)NMe 2 .
• Carbamate blocking groups have a stabilizing effect on the glycosidic bond and may be prepared under mild conditions.
• Preferred modified MenA saccharides contain n monosaccharide units, where at least h % of the monosaccharide units do not have -OH groups at both of positions 3 and 4.
• the value of h is 24 or more ( e.g. 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99 or 100) and is preferably 50 or more.
• the absent -OH groups are preferably blocking groups as defined above.
• Other preferred modified MenA saccharides comprise monosaccharide units, wherein at least s of the monosaccharide units do not have-OH at the 3 position and do not have -OH at the 4 position.
• the value of s is at least 1 ( e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90).
• the absent -OH groups are preferably blocking groups as defined above.
• Suitable modified MenA saccharides for use with the invention have the formula: wherein n is an integer from 1 to 100 (preferably an integer from 15 to 25); T is of the formula (A) or (B): each Z group is independently selected from OH or a blocking group as defined above; and each Q group is independently selected from OH or a blocking group as defined above; Y is selected from OH or a blocking group as defined above; E is H or a nitrogen protecting group; and wherein more than about 7% ( e.g. 8%, 9%, 10% or more) of the Q groups are blocking groups.
• Each of the n+2 Z groups may be the same or different from each other.
• each of the n+2 Q groups may be the same or different from each other.
• All the Z groups may be OH.
• at least 10%, 20, 30%, 40%, 50% or 60% of the Z groups may be OAc.
• about 70% of the Z groups are OAc, with the remainder of the Z groups being OH or blocking groups as defined above.
• At least about 7% of Q groups are blocking groups.
• at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100% of the Q groups are blocking groups.
• Meningococcal capsular polysaccharides are typically prepared by a process comprising the steps of polysaccharide precipitation (e.g. using a cationic detergent), ethanol fractionation, cold phenol extraction (to remove protein) and ultracentrifugation (to remove LPS) [ e.g. ref. 79].
• a more preferred process [25] involves polysaccharide precipitation followed by solubilisation of the precipitated polysaccharide using a lower alcohol.
• Precipitation can be achieved using a cationic detergent such as tetrabutylammonium and cetyltrimethylammonium salts (e.g.
• the polysaccharide may be further treated to remove contaminants. This is particularly important in situations where even minor contamination is not acceptable (e.g. for human vaccine production). This will typically involve one or more steps of filtration e.g. depth filtration, filtration through activated carbon may be used, size filtration and/or ultrafiltration. Once filtered to remove contaminants, the polysaccharide may be precipitated for further treatment and/or processing. This can be conveniently achieved by exchanging cations ( e.g. by the addition of calcium or sodium salts).
• capsular saccharides of the present invention may be obtained by total or partial synthesis e.g. Hib synthesis is disclosed in ref. 81, and MenA synthesis in ref. 82.
• compositions of the invention comprise capsular saccharides from at least two serogroups of N.meningitidis.
• the saccharides are preferably prepared separately (including any fragmentation, conjugation, modification, etc.) and then admixed to give a composition of the invention.
• composition comprises capsular saccharide from serogroup A
• serogroup A saccharide is not combined with the other saccharide(s) until shortly before use, in order to minimise the potential for hydrolysis.
• This can conveniently be achieved by having the serogroup A component (typically together with appropriate excipients) in lyophilised form and the other serogroup component(s) in liquid form (also with appropriate excipients), with the liquid components being used to reconstitute the lyophilised MenA component when ready for use.
• an aluminium salt adjuvant it is preferred to include the adjuvant in the vial containing the with the liquid vaccine, and to lyophilise the MenA component without adjuvant.
• a composition of the invention may thus be prepared from a kit comprising: (a) capsular saccharide from N.meningitidis serogroup A, in lyophilised form; and (b) the further antigens from the composition, in liquid form.
• the invention also provides a method for preparing a composition of the invention, comprising mixing a lyophilised capsular saccharide from N.meningitidis serogroup A with the further antigens, wherein said further antigens are in liquid form.
• the invention also provides a kit comprising: (a) a first container containing capsular saccharides from two or more of N.meningitidis serogroups C, W135 and Y, all in lyophilised form; and (b) a second container containing in liquid form (i) a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or more (e.g.
• the amount of an individual saccharide antigen will generally be between 1-50 ⁇ g (measured as mass of saccharide), with about 2.5 ⁇ g, 5 ⁇ g or 10 ⁇ g of each being preferred.
• A:C:W135:Y weight ratios of 1:1:1:1; 1:1:1:2; 2:1:1:1; 4:2:1:1; 8:4:2:1; 4:2:1:2; 8:4:1:2; 4:2:2:1; 2:2:1:1; 4:4:2:1; 2:2:1:2; 4:4:1:2; and 2:2:2:1 therefore, the amount represented by the number 1 is preferably about 2.5 ⁇ g, 5 ⁇ g or 10 ⁇ g.
• compositions For a 1:1:1:1 ratio A:C:W:Y composition and a 10 ⁇ g per saccharide, therefore, 40 ⁇ g saccharide is administered per dose.
• Preferred compositions have about the following ⁇ g saccharide per dose: A 10 0 0 0 10 5 2.5 C 10 10 5 2.5 5 5 2.5 W135 10 10 5 2.5 5 5 2.5 Y 10 10 5 2.5 5 5 2.5
• compositions of the invention comprise less than 50 ⁇ g meningococcal saccharide per dose.
• Other preferred compositions comprise ⁇ 40 ⁇ g meningococcal saccharide per dose.
• Other preferred compositions comprise ⁇ 30 ⁇ g meningococcal saccharide per dose.
• Other preferred compositions comprise ⁇ 25 ⁇ g meningococcal saccharide per dose.
• Other preferred compositions comprise ⁇ 20 ⁇ g meningococcal saccharide per dose.
• Other preferred compositions comprise ⁇ 10 ⁇ g meningococcal saccharide per dose but, ideally, compositions of the invention comprise at least 10 ⁇ g meningococcal saccharide per dose.
• MenjugateTM and NeisVacTM MenC conjugates use a hydroxide adjuvant, whereas MeningitecTM uses a phosphate. It is possible in compositions of the invention to adsorb some antigens to an aluminium hydroxide but to have other antigens in association with an aluminium phosphate.
• P a phosphate
• composition includes a H.influenzae type B antigen
• it will typically be a Hib capsular saccharide antigen. Saccharide antigens from H.influenzae b are well known.
• the Hib saccharide is covalently conjugated to a carrier protein, in order to enhance its immunogenicity, especially in children.
• a carrier protein in order to enhance its immunogenicity, especially in children.
• the invention may use any suitable Hib conjugate.
• Suitable carrier proteins are described below, and preferred carriers for Hib saccharides are CRM 197 ('HbOC'), tetanus toxoid ('PRP-T') and the outer membrane complex of N.meningitidis ('PRP-OMP').
• the saccharide moiety of the conjugate may be a polysaccharide (e.g. full-length polyribosylribitol phosphate (PRP)), but it is preferred to hydrolyse polysaccharides to form oligosaccharides (e.g. MW from ⁇ 1 to ⁇ 5 kDa).
• polysaccharide e.g. full-length polyribosylribitol phosphate (PRP)
• PRP polyribosylribitol phosphate
• a preferred conjugate comprises a Hib oligosaccharide covalently linked to CRM 197 via an adipic acid linker [92, 93]. Tetanus toxoid is also a preferred carrier.
• compositions of the invention may comprise more than one Hib antigen.
• composition includes a Hib saccharide antigen
• the composition includes an aluminium phosphate adjuvant then the Hib antigen may be adsorbed to the adjuvant [94] or it may be non-adsorbed [95].
• Hib antigens may be lyophilised e.g. together with meningococcal antigens.
• composition includes a S.pneumoniae antigen
• a S.pneumoniae antigen it will typically be a capsular saccharide antigen which is preferably conjugated to a carrier protein [ e.g. refs. 26-28]. It is preferred to include saccharides from more than one serotype of S.pneumoniae. For example, mixtures of polysaccharides from 23 different serotype are widely used, as are conjugate vaccines with polysaccharides from between 5 and 11 different serotypes [96].
• PrevNarTM [97] contains antigens from seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) with each saccharide individually conjugated to CRM 197 by reductive amination, with 2 ⁇ g of each saccharide per 0.5ml dose (4 ⁇ g of serotype 6B), and with conjugates adsorbed on an aluminium phosphate adjuvant.
• Compositions of the invention preferably include at least serotypes 6B, 14, 19F and 23F. Conjugates may be adsorbed onto an aluminium phosphate.
• the composition may include one or more polypeptide antigens.
• Genome sequences for several strains of pneumococcus are available [98,99] and can be subjected to reverse vaccinology [100-103] to identify suitable polypeptide antigens [104,105].
• the composition may include one or more of the following antigens: PhtA, PhtD, PhtB, PhtE, SpsA, LytB, LytC, LytA, Sp125, Sp101, Sp128 and Sp130, as defined in reference 106.
• the composition may include both saccharide and polypeptide antigens from pneumococcus. These may be used in simple admixture, or the pneumococcal saccharide antigen may be conjugated to a pneumococcal protein. Suitable carrier proteins for such embodiments include the antigens listed in the previous paragraph [106].
• Pneumococcal antigens may be lyophilised e.g. together with meningococcal and/or Hib antigens.
• Capsular saccharides in compositions of the invention will usually be conjugated to carrier protein(s).
• conjugation enhances the immunogenicity of saccharides as it converts them from T-independent antigens to T-dependent antigens, thus allowing priming for immunological memory.
• Conjugation is particularly useful for paediatric vaccines and is a well known technique [ e.g. reviewed in refs. 107 and 83-91].
• Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria toxoid or tetanus toxoid.
• the CRM 197 mutant diphtheria toxin [74,108,109] is particularly preferred.
• Other suitable carrier proteins include the N.meningitidis outer membrane protein [63], synthetic peptides [64,65], heat shock proteins [66,67], pertussis proteins [68,69], cytokines [71], lymphokines [71], hormones [71], growth factors [71], artificial proteins comprising multiple human CD4 + T cell epitopes from various pathogen-derived antigens [110], protein D from H.influenzae [70,111], pneumococcal surface protein PspA [112], iron-uptake proteins [73], toxin A or B from C.difficile [72], etc.
• Preferred carriers are diphtheria toxoid, tetanus toxoid, H.influenza
• composition of the invention it is possible to use more than one carrier protein e.g. to reduce the risk of carrier suppression.
• different carrier proteins can be used for different serogroups e.g. serogroup A saccharides might be conjugated to CRM 197 while serogroup C saccharides might be conjugated to tetanus toxoid.
• more than one carrier protein for a particular saccharide antigen e.g. serogroup A saccharides might be in two groups, with some conjugated to CRM 197 and others conjugated to tetanus toxoid. In general, however, it is preferred to use the same carrier protein for all saccharides.
• a single carrier protein might carry more than one saccharide antigen [113].
• a single carrier protein might have conjugated to it saccharides from serogroups A and C.
• saccharides can be mixed prior to the conjugation reaction. In general, however, it is preferred to have separate conjugates for each serogroup.
• Conjugates with a saccharide:protein ratio (w/w) of between 1:5 (i.e. excess protein) and 5:1 (i.e. excess saccharide) are preferred. Ratios between 1:2 and 5:1 are preferred, as are ratios between 1:1.25 and 1:2.5 are more preferred. Excess carrier protein is preferred for MenA and MenC.
• Conjugates may be used in conjunction with free carrier protein [114].
• the unconjugated form is preferably no more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight.
• the saccharide will typically be activated or functionalised prior to conjugation. Activation may involve, for example, cyanylating reagents such as CDAP (e.g. 1-cyano-4-dimethylamino pyridinium tetrafluoroborate [115,116, etc .]).
• CDAP cyanylating reagents
• Other suitable techniques use carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU; see also the introduction to reference 89).
• Linkages via a linker group may be made using any known procedure, for example, the procedures described in references 117 and 118.
• One type of linkage involves reductive amination of the polysaccharide, coupling the resulting amino group with one end of an adipic acid linker group, and then coupling a protein to the other end of the adipic acid linker group [87,119,120].
• Other linkers include B-propionamido [121], nitrophenyl-ethylamine [122], haloacyl halides [123], glycosidic linkages [124], 6-aminocaproic acid [125], ADH [126], C 4 to C 12 moieties [127] etc.
• direct linkage can be used. Direct linkages to the protein may comprise oxidation of the polysaccharide followed by reductive amination with the protein, as described in, for example, references 128 and 129.
• Another preferred reaction uses CDAP activation with a protein D carrier e.g. for MenA or MenC.
• composition of the invention includes a conjugated oligosaccharide
• oligosaccharide preparation precedes conjugation
• compositions of the invention should not include complex or undefined mixtures of antigens, which are typical characteristics of OMVs.
• one way in which the invention can be applied to OMVs is where OMVs are to be administered in a multiple dose schedule.
• N.meningitidis serogroup B microvesicles [132], 'native OMVs' [133], blebs or outer membrane vesicles [ e.g. refs. 134 to 139, etc .].
• These may be prepared from bacteria which have been genetically manipulated [140-143] e.g. to increase immunogenicity (e.g. hyper-express immunogens), to reduce toxicity, to inhibit capsular polysaccharide synthesis, to down-regulate PorA expression, etc. They may be prepared from hyperblebbing strains [144-147].
• Vesicles from a non-pathogenic Neisseria may be included [148].
• OMVs may be prepared without the use of detergents [149,150]. They may express non-Neisserial proteins on their surface [151]. They may be LPS-depleted. They may be mixed with recombinant antigens [134,152]. Vesicles from bacteria with different class I outer membrane protein subtypes may be used e.g. six different subtypes [153,154] using two different genetically-engineered vesicle populations each displaying three subtypes, or nine different subtypes using three different genetically-engineered vesicle populations each displaying three subtypes, etc. Useful subtypes include: P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1; P1.18-1,3,6.
• composition of the invention is preferably an immunogenic composition, and the invention provides an immunogenic composition of the invention for use as a medicament.
• the invention also provides a method for raising an antibody response in a mammal, comprising administering an immunogenic composition of the invention to the mammal.
• the antibody response is preferably a protective and/or bactericidal antibody response.
• the invention also provides a method for protecting a mammal against a Neisserial (e.g. meningococcal) infection, comprising administering to the mammal an immunogenic composition of the invention.
• a Neisserial e.g. meningococcal
• the invention also provides the use of at least two of antigens (a), (b) and (c) as defined above in the manufacture of a medicament for preventing Neisserial (e.g. meningococcal) infection in a mammal.
• Neisserial e.g. meningococcal
• the mammal is preferably a human.
• the human may be an adult or, preferably, a child.
• Immunogenic compositions of the invention may be used therapeutically (i. e. to treat an existing infection) or prophylactically (i.e. to prevent future infection).
• the uses and methods are particularly useful for preventing/treating diseases including, but not limited to, meningitis (particularly bacterial meningitis) and bacteremia.
• Efficacy of therapeutic treatment can be tested by monitoring Neisserial infection after administration of the composition of the invention.
• Efficacy of prophylactic treatment can be tested by monitoring immune responses after administration of the composition.
• Immunogenicity of compositions of the invention can be determined by administering them to test subjects (e.g. children 12-16 months age, or animal models [155]) and then determining standard parameters including serum bactericidal antibodies (SBA) and ELISA titres (GMT) of total and high-avidity anti-capsule IgG.
• SBA serum bactericidal antibodies
• GTT ELISA titres
• compositions of the invention can confer an antibody titre in a patient that is superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects.
• Antigens with an associated antibody titre above which a host is considered to be seroconverted against the antigen are well known, and such titres are published by organisations such as WHO.
• Preferably more than 80% of a statistically significant sample of subjects is seroconverted, more preferably more than 90%, still more preferably more than 93% and most preferably 96-100%.
• compositions of the invention will generally be administered directly to a patient.
• Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, aural, pulmonary or other mucosal administration.
• Intramuscular administration to the thigh or the upper arm is preferred.
• Injection may be via a needle (e.g. a hypodermic needle), but needle-free injection may alternatively be used.
• a typical intramuscular dose is 0.5 ml.
• the invention may be used to elicit systemic and/or mucosal immunity.
• Dosage treatment can be a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. A primary dose schedule may be followed by a booster dose schedule. Suitable timing between priming doses ( e.g. between 4-16 weeks), and between priming and boosting, can be routinely determined.
• the immunogenic composition of the invention will generally include a pharmaceutically acceptable carrier, which can be any substance that does not itself induce the production of antibodies harmful to the patient receiving the composition, and which can be administered without undue toxicity.
• Suitable carriers can be large, slowly-metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
• Pharmaceutically acceptable carriers can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Liposomes are suitable carriers. A thorough discussion of pharmaceutical carriers is available in ref. 156.
• compositions of the invention may be prepared in various forms.
• the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared.
• the composition may be prepared for topical administration e.g. as an ointment, cream or powder.
• the composition be prepared for oral administration e.g. as a tablet or capsule, or as a syrup (optionally flavoured).
• the composition may be prepared for pulmonary administration e.g. as an inhaler, using a fine powder or a spray.
• the composition may be prepared as a suppository or pessary.
• the composition may be prepared for nasal, aural or ocular administration e.g. as drops.
• compositions of the invention may be isotonic with respect to humans.
• Immunogenic compositions comprise an immunologically effective amount of immunogen, as well as any other of other specified components, as needed.
• 'immunologically effective amount' it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated ( e.g. non-human primate, primate, etc .), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Dosage treatment may be a single dose schedule or a multiple dose schedule ( e.g. including booster doses). The composition may be administered in conjunction with other immunoregulatory agents.
• An immunogenic composition will generally include an adjuvant.
• Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (A) MF59 (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer) [see Chapter 10 of ref. 158; see also ref. 159]; (B) microparticles ( i.e. a particle of ⁇ 100nm to ⁇ 150 ⁇ m in diameter, more preferably ⁇ 200nm to ⁇ 30 ⁇ m in diameter, and most preferably ⁇ 500nm to ⁇ 10 ⁇ m in diameter) formed from materials that are biodegradable and non-toxic (e.g.
• Ribi TM adjuvant system Ribi Immunochem
• Ribi Immunochem Ribi Immunochem
• MPL monophosphorylipid A
• TDM trehalose dimycolate
• CWS cell wall skeleton
• saponin adjuvants such as QuilA or QS21 [see Chapter 22 of ref. 158], also known as StimulonTM
• H chitosan [ e.g.
• cytokines such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g. interferon-y), macrophage colony stimulating factor, tumor necrosis factor, etc. [see Chapters 27 & 28 of ref. 158], RC529;
• a saponin e.g.
• a polyoxyethylene ether or a polyoxyethylene ester [167] a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol [168] or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol [169];
• an immunostimulatory oligonucleotide e.g.
• Aluminium salts (aluminium phosphates and particularly hydroxyphosphates, and/or hydroxides and particularly oxyhydroxide) and MF59 are preferred adjuvants for parenteral immunisation. Toxin mutants are preferred mucosal adjuvants.
• Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl- sn -glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.
• thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
• nor-MDP N-acetyl-normuramyl-L-alanyl-D-isoglutamine
• a bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA.
• a promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site.
• a bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene.
• Constitutive expression may occur in the absence of negative regulatory elements, such as the operator.
• positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence.
• An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (E. coli) [ Raibaud et al. (1984) Annu. Rev. Genet. 18:173 ].
• Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.
• Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose ( lac ) [ Chang et al. (1977) Nature 198:1056 ], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan ( trp ) [ Goeddel et al. (1980) Nuc. Acids Res. 8:4057 ; Yelverton et al. (1981) Nucl. Acids Res. 9:731 ; US patent 4,738,921 ; EP-A-0036776 and EP-A-0121775 ].
• ⁇ -lactamase ( bla ) promoter system [ Weissmann (1981) "The cloning of interferon and other mistakes.” In Interferon 3 (ed. I. Gresser )], bacteriophage lambda PL [ Shimatake et al. (1981) Nature 292:128 ] and T5 [ US patent 4,689,406 ] promoter systems also provide useful promoter sequences.
• Another promoter of interest is an inducible arabinose promoter (pBAD).
• synthetic promoters which do not occur in nature also function as bacterial promoters.
• transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [ US patent 4,551,433 ].
• the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor [ Amann et al. (1983) Gene 25:167 ; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21 ].
• a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription.
• a naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes.
• the bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [ Studier et al. (1986) J. Mol. Biol. 189:113 ; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074 ].
• a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region ( EPO-A-0 267 851 ).
• an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes.
• the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [ Shine et al. (1975) Nature 254:34 ].
• SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' and of E. coli 16S rRNA [ Steitz et al.
• a promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-terminal peptidase ( EP-A-0219237 ).
• transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.
• expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g. plasmids) capable of stable maintenance in a host, such as bacteria.
• a replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification.
• a replicon may be either a high or low copy number plasmid.
• a high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150.
• a host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.
• the expression constructs can be integrated into the bacterial genome with an integrating vector.
• Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome.
• integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome ( EP-A-0127328 ). Integrating vectors may also be comprised of bacteriophage or transposon sequences.
• extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed.
• Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [ Davies et al. (1978) Annu. Rev. Microbiol. 32:469 ].
• Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.
• Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.
• Expression and transformation vectors have been developed for transformation into many bacteria.
• expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtilis [ Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582 ; EP-A-0 036 259 and EP-A-0 063 953 ; WO 84/04541 ], Escherichia coli [ Shimatake et al. (1981) Nature 292:128 ; Amann et al. (1985) Gene 40:183 ; Studier et al. (1986) J. Mol. Biol.
• Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl 2 or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See e . g . [ Masson et al. (1989) FEMS Microbiol. Lett. 60:273 ; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582 ; EP-A-0 036 259 and EP-A-0 063 953 ; WO 84/04541 , Bacillus], [ Miller et al. (1988) Proc.
• the invention preferably excludes: (a) amino acid and nucleic acid sequences available in public sequence databases (e.g. GenBank or GENESEQ) prior to 22nd November 2002; (b) amino acid and nucleic acid sequences disclosed in patent applications having a filing date or, where applicable, a priority date prior to 22nd November 2002.
• SEQ ID entries in the any of the references cited herein may be excluded e.g. reference Error! Bookmark not defined.
• composition comprising X may consist exclusively of X or may include something additional e.g. X + Y.
• meningococcal classification includes serotype, serosubtype and then immunotype, and the standard nomenclature lists serogroup, serotype, serosubtype, and immunotype, each separated by a colon e.g. B:4:P1.15:L3,7,9.
• serogroup B some lineages cause disease often (hyperinvasive), some lineages cause more severe forms of disease than others (hypervirulent), and others rarely cause disease at all. Seven hypervirulent lineages are recognised, namely subgroups I, III and IV-1, ET-5 complex, ET-37 complex, A4 cluster and lineage 3.
• multilocus enzyme electrophoresis MLEE
• multilocus sequence typing MLST
• ST32, ST44, ST8 and ST11 complexes The four main hypervirulent clusters are ST32, ST44, ST8 and ST11 complexes.
• alkyl refers to alkyl groups in both straight and branched forms, The alkyl group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -NH- or -S-. The alkyl group may also be interrupted with 1, 2 or 3 double and/or triple bonds. However, the term “alkyl” usually refers to alkyl groups having no heteroatom interruptions or double or triple bond interruptions. Where reference is made to C 1-12 alkyl, it is meant the alkyl group may contain any number of carbon atoms between 1 and 12 (e.g.
• the alkyl group may contain any number of carbon atoms between 1 and 6 ( e.g. C 1 , C 2 , C 3 , C 4 , C 5 , C 6 ).
• cycloalkyl includes cycloalkyl, polycycloalkyl, and cycloalkenyl groups, as well as combinations of these with alkyl groups, such as cycloalkylalkyl groups.
• the cycloalkyl group may be interrupted with 1, 2 or 3 heteroatoms selected from -O-, -NH- or -S-.
• cycloalkyl usually refers to cycloalkyl groups having no heteroatom interruptions Examples of cycloalkyl groups include cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexylmethyl and adamantyl groups.
• C 3-12 cycloalkyl it is meant that the cycloalkyl group may contain any number of carbon atoms between 3 and 12 (e.g. C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 ).
• aryl refers to an aromatic group, such as phenyl or naphthyl. Where reference is made to C 5-12 aryl, it is meant that the aryl group may contain any number of carbon atoms between 5 and 12 ( e.g. C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 ).
• C 5-12 aryl-C 1-6 alkyl refers to groups such as benzyl, phenylethyl and naphthylmethyl.
• Nitrogen protecting groups include silyl groups (such as TMS, TES, TBS, TIPS), acyl derivatives (such as phthalimides, trifluoroacetamides, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl (Boc), benzyloxycarbonyl (Z or Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), 2-(trimethylsilyl)ethoxy carbonyl, 2,2,2-trichloroethoxycarbonyl (Troc)), sulfonyl derivatives (such as ⁇ -trimethylsilylethanesulfonyl (SES)), sulfenyl derivatives, C 1-12 alkyl, benzyl, benzhydryl, trityl, 9-phenylfluorenyl etc.
• a preferred nitrogen protecting group is Fmoc.
• strains representative of the genetic and geographic diversity of the N.meningitidis population were selected for further investigation of NMB1870. Strains derive from 19 different countries, 73% belong to serogroup B, and 32 were isolated in the last five years.
• the strain panel mostly includes serogroup B strains, a few strains of serogroups A, C, Y, W-135 and Z, and one strain each of N.gonorrhoeae and N.cinerea. Strains are disclosed in more detail in references 173 & 174. Some strains are available from the ATCC ( e.g. strain MC58 is available under reference BAA-335).
• the strain lnp17592 sequence of NMB1870 is seen in the W-135 Haji serogroup. Within the Haji strains, the NadA sequence (SEQ ID NO: 1) is a recombination between alleles 2 and 3 [173,174].

Applications Claiming Priority (2)

Related Parent Applications (2)

Publications (2)

Family

ID=9948377

Family Applications (4)

Family Applications Before (1)

Family Applications After (2)

Country Status (19)

Cited By (1)

Families Citing this family (95)

Citations (107)

Family Cites Families (52)

• 2002
  • 2002-11-22 GB GBGB0227346.4A patent/GB0227346D0/en not_active Ceased
• 2003
  • 2003-11-21 JP JP2004554854A patent/JP4767540B2/ja not_active Expired - Lifetime
  • 2003-11-21 PT PT37805280T patent/PT1562983E/pt unknown
  • 2003-11-21 NZ NZ540206A patent/NZ540206A/en not_active IP Right Cessation
  • 2003-11-21 DK DK10182503.2T patent/DK2261239T3/en active
  • 2003-11-21 DK DK10178923.8T patent/DK2258716T3/da active
  • 2003-11-21 PT PT101825032T patent/PT2261239T/pt unknown
  • 2003-11-21 CA CA002507009A patent/CA2507009A1/fr not_active Abandoned
  • 2003-11-21 CA CA2960687A patent/CA2960687A1/fr not_active Abandoned
  • 2003-11-21 ES ES10178923.8T patent/ES2509915T3/es not_active Expired - Lifetime
  • 2003-11-21 RU RU2005119640/13A patent/RU2336091C2/ru active
  • 2003-11-21 HU HUE10182503A patent/HUE034257T2/en unknown
  • 2003-11-21 SI SI200332369T patent/SI2258716T1/sl unknown
  • 2003-11-21 US US10/536,215 patent/US20060251670A1/en not_active Abandoned
  • 2003-11-21 EP EP03780528.0A patent/EP1562983B2/fr not_active Expired - Lifetime
  • 2003-11-21 EP EP10179140A patent/EP2258717A3/fr not_active Withdrawn
  • 2003-11-21 MX MXPA05005442A patent/MXPA05005442A/es active IP Right Grant
  • 2003-11-21 SI SI200332317T patent/SI1562983T1/sl unknown
  • 2003-11-21 EP EP10178923.8A patent/EP2258716B1/fr not_active Revoked
  • 2003-11-21 SI SI200332544T patent/SI2261239T1/sl unknown
  • 2003-11-21 ES ES03780528.0T patent/ES2436747T5/es not_active Expired - Lifetime
  • 2003-11-21 AU AU2003288681A patent/AU2003288681B2/en not_active Expired
  • 2003-11-21 EP EP10182503.2A patent/EP2261239B1/fr not_active Expired - Lifetime
  • 2003-11-21 PT PT101789238T patent/PT2258716E/pt unknown
  • 2003-11-21 WO PCT/IB2003/006320 patent/WO2004048404A2/fr active Application Filing
  • 2003-11-21 ES ES10182503.2T patent/ES2637065T3/es not_active Expired - Lifetime
  • 2003-11-21 CN CNB2003801076879A patent/CN100381464C/zh not_active Expired - Lifetime
  • 2003-11-21 BR BR0316501-9A patent/BR0316501A/pt not_active IP Right Cessation
  • 2003-11-21 DK DK03780528.0T patent/DK1562983T3/da active
• 2006
  • 2006-08-08 HK HK06108816.9A patent/HK1088342A1/xx not_active IP Right Cessation
• 2010
  • 2010-03-16 JP JP2010059915A patent/JP5564297B2/ja not_active Expired - Lifetime
• 2012
  • 2012-02-01 US US13/364,264 patent/US8980286B2/en not_active Expired - Lifetime
  • 2012-02-06 US US13/367,289 patent/US20120148618A1/en not_active Abandoned
• 2013
  • 2013-03-28 JP JP2013068018A patent/JP2013176371A/ja active Pending
• 2014
  • 2014-09-11 CY CY20141100741T patent/CY1115778T1/el unknown
• 2015
  • 2015-10-20 US US14/918,417 patent/US9550814B2/en not_active Expired - Lifetime
• 2016
  • 2016-11-14 US US15/351,286 patent/US20170290902A1/en not_active Abandoned
• 2017
  • 2017-06-21 CY CY20171100655T patent/CY1119019T1/el unknown
  • 2017-07-05 US US15/641,955 patent/US10328142B2/en not_active Expired - Lifetime

Patent Citations (112)

Non-Patent Citations (123)

Also Published As

Similar Documents

Legal Events